OBJECTIVE: To determine the presence of a possible correlation between prostate specific antigen (PSA) and the findings from digital rectal examination (DRE) in patients with prostate cancer or benign prostatic hyperplasia. DESIGN: Retrospective, longitudinal, and observational study of diagnostic tests. SETTING: Gregorio Marañón Hospital, Madrid, Spain. PARTICIPANTS: It included 706 patients with a PSA in the range 4.1-20 ng/mL, studied owing to suspected prostate cancer localised using DRE and transrectal ultrasound, in whom randomised prostate biopsies were performed. MAIN MEASUREMENTS: Total PSA and free/total PSA ratio and DRE normal or suspicious were studied as main variables. The outcome variable was the diagnosis of prostatic cancer by biopsy. RESULTS: With a detection of cancer of 28.2%, there were no statistically significant differences in the PSA or free/total PSA ratio mean values between patients with or without suspicious DRE. The analysis using ROC curves (with a 95% confidence interval) between both groups of patients found the same sensitivity of 95% with a similar specificity of 6% and 10%, respectively, for a PSA of 4.8 ng/mL. CONCLUSIONS: In the PSA range of 4.1-20 ng/mL, the findings of DRE appeared as a variable unrelated to the increase in PSA or the free/total PSA ratio and, therefore are not indicative of a lesser or greater volume of a tumour producing PSA. The performing of this examination could be considered as optional.
OBJECTIVE: To determine the presence of a possible correlation between prostate specific antigen (PSA) and the findings from digital rectal examination (DRE) in patients with prostate cancer or benign prostatic hyperplasia. DESIGN: Retrospective, longitudinal, and observational study of diagnostic tests. SETTING: Gregorio Marañón Hospital, Madrid, Spain. PARTICIPANTS: It included 706 patients with a PSA in the range 4.1-20 ng/mL, studied owing to suspected prostate cancer localised using DRE and transrectal ultrasound, in whom randomised prostate biopsies were performed. MAIN MEASUREMENTS: Total PSA and free/total PSA ratio and DRE normal or suspicious were studied as main variables. The outcome variable was the diagnosis of prostatic cancer by biopsy. RESULTS: With a detection of cancer of 28.2%, there were no statistically significant differences in the PSA or free/total PSA ratio mean values between patients with or without suspicious DRE. The analysis using ROC curves (with a 95% confidence interval) between both groups of patients found the same sensitivity of 95% with a similar specificity of 6% and 10%, respectively, for a PSA of 4.8 ng/mL. CONCLUSIONS: In the PSA range of 4.1-20 ng/mL, the findings of DRE appeared as a variable unrelated to the increase in PSA or the free/total PSA ratio and, therefore are not indicative of a lesser or greater volume of a tumour producing PSA. The performing of this examination could be considered as optional.
Authors: Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick Journal: J Urol Date: 1994-05 Impact factor: 7.450
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245